OKYO Pharma to Present Dry Eye Disease Phase 2 Results at Eyecelerator 2024

OKYO Pharma, a biopharmaceutical firm, is set to present Phase 2 data for its dry eye disease treatment at the Eyecelerator 2024 event. This conference, a collaboration between the American Academy of Ophthalmology and the American Society of Cataract and Refractive Surgery, is designed to foster innovation in the field of eye care. The presentation will be led by Gary Jacob, the company's CEO, at the Omni Boston Hotel on April 4, 2024.

Eyecelerator aims to connect scientific experts and entrepreneurs with investors and partners who are keen on advancing eye care solutions. It offers a platform for showcasing industry progress, investment insights, and groundbreaking products that are set to revolutionize ophthalmology. The event also serves as a networking opportunity and a chance to discover new market opportunities.

OKYO Pharma is dedicated to developing new treatments for inflammatory dry eye disease and neuropathic corneal pain, conditions that currently lack FDA-approved therapies. The company is listed on the NASDAQ Capital Market and is actively working on advancing its Phase 2 trial for OK-101, a potential treatment for neuropathic corneal pain.